ImmunoGen (IMGN) Pops Higher Following Positive T-DM1 Phase III Results
Tweet
Share
E-mailGet Alerts IMGN Hot Sheet
Join SI Premium – FREE
ImmunoGen (Nasdaq: IMGN) is moving higher ahead of the bell Friday following positive results from its T-DM1 EMILIA Phase III trial. Shares are indicated about 12 percent higher.
T-DM1 (trastuzumab emtansine) consists of ImmunoGen's potent cancer-killing agent, DM1, attached to the HER2-targeting antibody.
For more color on the results, click here.
T-DM1 (trastuzumab emtansine) consists of ImmunoGen's potent cancer-killing agent, DM1, attached to the HER2-targeting antibody.
For more color on the results, click here.
Create E-mail Alert Related Categories
Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
